Development of an Fn14 agonistic antibody as an anti-tumor agent

mAbs

Volumn 3, Issue 4, 2011, Pages 362-375

  Michaelson, Jennifer S ^a   Amatucci, Aldo ^a   Kelly, Rebecca ^a   Su, Lihe ^a   Garber, Ellen ^a   Day, Eric S ^a   Berquist, Lisa ^a   Cho, Sandy ^a   Li, You ^a   Parr, Michael ^a   Willen, Laure ^b   Schneider, Pascal ^b   Wortham, Kathleen ^a   Burkly, Linda C ^a   Hsu, Yen Ming ^a   Joseph, Ingrid B J K ^a  

^a BIOGEN   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Agonist; Apoptosis; Fn14; Monoclonal antibody; TWEAK; Xenograft

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BIIB 036; FC RECEPTOR; FN14; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK; TWEAK ADENOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CELL FUNCTION; COLON TUMOR; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STOMACH TUMOR; TUMOR XENOGRAFT;

EID: 79960091768     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.4.16090     Document Type: Article

References (42)

1. Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets 2008; 8:124-31.
2. Buchsbaum DJ, Zhou T, Lobuglio AF. TRAIL receptor-targeted therapy. Future Oncology (London, England) 2006; 2:493-508. (Pubitemid 44304608)
3. Wiezorek J, Holland P, Graves J. Death receptor agonists as a targeted therapy for cancer. Clin Cancer Res 2010; 16:1701-8.
4. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007; 40:1-16. (Pubitemid 350088500)
5. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, et al. TWEAK, A new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997; 272:32401-10. (Pubitemid 28011923)
6. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003; 14:241-9.
7. Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. A J Pathol 2000; 156:1253-61. (Pubitemid 30660004)
8. Girgenrath M, Weng S, Kostek CA, Browning B, Wang M, Brown SA, et al. TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J 2006; 25:5826-39. (Pubitemid 44967766)
9. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, Zheng TS, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest 2005; 115:2330-40. (Pubitemid 41266195)
10. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15:837-46.
11. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.[ erratum appears in Cancer Res 2002; 62:4532]. Cancer Res 2002; 62:2890-6.
12. Michaelson JS, Cho S, Browning B, Zheng TS, Lincecum JM, Wang MZ, et al. Tweak induces mammary epithelial branching morphogenesis. Oncogene 2005; 24:2613-24. (Pubitemid 40593089)
13. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is upregulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. A J Pathol 2003; 162:1313-21. (Pubitemid 36350675)
14. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased Fibroblast Growth Factor-Inducible 14 Expression Levels Promote Glioma Cell Invasion via Rac1 and Nuclear Factor{kappa}B and Correlate with Poor Patient Outcome. Cancer Res 2006; 66:9535-42. (Pubitemid 44623652)
15. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, Xu Y, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006; 25:3346-56. (Pubitemid 43846319)
16. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 2010; 16:497-508.
17. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008; 6:725-34.
18. Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factorkappaB activation. Biochem J 2003; 371:395-403.
19. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NFκB2 p100 processing and long lasting NFκB activation. J Biol Chem 2003; 278:36005-12. (Pubitemid 37139919)
20. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, et al. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007; 178:8183-94. (Pubitemid 46898091)
21. Nakayama M, Harada N, Okumura K, Yagita H. Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Comm 2003; 306:819-25. (Pubitemid 36776204)
22. Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H, et al. Multiple pathways of TWEAK-induced cell death. J Immunol 2002; 168:734-43. (Pubitemid 34049574)
23. Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P. TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol 1999; 29:1785-92. (Pubitemid 29265533)
24. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, Schneider P, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008; 182:171-84. (Pubitemid 352008630)
25. Wilson CA, Browning JL. Death of HT29 adenocarcinoma cells induced by TNF family receptor activation is caspase-independent and displays features of both apoptosis and necrosis. Cell Death Diff 2002; 9:1321-33. (Pubitemid 36097702)
26. Angal S, King DJ, Bodmer MW, Turner A, Lawson AD, Roberts G, et al. A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol Immunol 1993; 30:105-8. (Pubitemid 223036868)
27. Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 2010; 9:2593-604.
28. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol 2003; 23:1428-40. (Pubitemid 36177050)
29. Co MS, Avdalovic NM, Caron PC, Avdalovic MV, Scheinberg DA, Queen C. Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol 1992; 148:1149-54.
30. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D, et al. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ 2009; 16:1445-59.
31. Sarmay G, Lund J, Rozsnyay Z, Gergely J, Jefferis R. Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor. Mol Immunol 1992; 29:633-9.
32. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003; 170:341-8. (Pubitemid 36026158)
33. Dogra C, Changotra H, Wedhas N, Qin X, Wergedal JE, Kumar A. TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J 2007; 21:1857-69. (Pubitemid 46855631)
34. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, Ambrose C, et al. Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 2002; 4:126-33. (Pubitemid 34257346)
35. Zimmermann M, Koreck A, Meyer N, Basinski T, Meiler F, Simone B, et al. TNF-like weak inducer of apoptosis (TWEAK) and TNFalpha cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol 2011; 127:200-7.
36. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19:101-13.
37. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA, et al. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 2007; 121:2132-9. (Pubitemid 47585591)
38. Michaelson JS, Burkly LC. Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ 2009; 49:145-60.
39. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999; 274:8455-9. (Pubitemid 29164634)
40. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23:594-600. (Pubitemid 36438071)
41. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004; 64:8968-72. (Pubitemid 39665505)
42. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, et al. Functional expression of TWEAK in human colonic adenocarcinoma cells. Int J Oncol 2005; 26:87-93.